ClinicalTrials.gg
TerminatedNCT04762602Updated Mar 27, 2026Results posted

A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations

A Phase 1 interventional study of HMPL-306 in Isocitrate Dehydrogenase Gene Mutation, sponsored by Hutchmed. Terminated at 11 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-27.

Sponsored by Hutchmed · Phase 1, Interventional, and Treatment

Why this study was terminated
The study was terminated based on strategic evaluation of the clinical development of HMPL-306 with no safety concerns

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
42
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 328 studies in Cholangiocarcinoma with a site in United States — 72 open to participants now, 111 under way, 7 of them phase 3. Cholangiocarcinoma · United States.

Enrollment
142nd of 279
42 · median 44
Started
2021
with 24 others
Phase 1
85 of 328
14 open now
Registered
208th of 328
by date

Among the 328 studies in Cholangiocarcinoma with a site in United States, this one is the 142nd largest by enrollment of the 279 interventional ones that give a count, is one of 25 that started in 2021, is one of 85 in phase 1, and was the 208th registered.

Cholangiocarcinoma

825 studies on the registry are indexed under Cholangiocarcinoma; 287 are open to participants now.

Browse Cholangiocarcinoma studies →

Open to participants now

72 of the 328 studies in Cholangiocarcinoma with a site in United States are open now. Recruiting first, the newest first:

67 more — sign in →

All 72 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 211 Cholangiocarcinoma studies recruiting now, 141 (67%) set no upper age limit and 49 (23%) stop at 75 or younger; 10 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 328 studies in Cholangiocarcinoma with a site in United States, or all of them as a file.
02

Study summary

An open label single-arm clinical trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of HMPL-306 in advanced or metastatic solid tumors with IDH mutation.

Read the detailed description

HMPL-306 is a dual IDH1/2 inhibitor

This is a phase 1, open-label, multicenter study to evaluate the safety and tolerability of HMPL-306 administered orally in the treatment of subjects with advanced or metastatic solid tumors with IDH mutation. The study consists of 2 parts: Part 1 (dose escalation) and Part 2 (dose expansion). The dose escalation part will determine the MTD/RP2D. The dose expansion part will administer the MTD/RP2D to mIDH-positive solid tumor malignancies including, but not limited to, cholangiocarcinoma, skeletal chondrosarcoma, low-grade glioma, perioperative low-grade glioma

03

Conditions studied

  • Isocitrate Dehydrogenase Gene Mutation

Keywords

  • Cholangiocarcinoma
  • Skeletal chondrosarcoma
  • Glioma
  • IDH Mutation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

Subjects are eligible for enrollment into this study if they meet any of the following criteria (NOTE: This is not an exhaustive list):

  • Subjects aged ≥18 years.
  • performance status 0 or 1
  • Subjects must have a documented IDH mutation per immunohistochemistry (IHC), polymerase chain reaction (PCR), or next generation sequencing (NGS) testing of tumor tissue.
  • Subjects must have or cytologically documented, advanced or solid of any type that has recurred or progressed on available standard treatment and for which no curative therapy exists.

Key Exclusion Criteria:

Subjects are not eligible for enrollment into this study if they meet any of the following criteria (NOTE: This is not an exhaustive list):

  • Subjects who received an agent \<14 days prior to their first day of study drug administration
  • Subjects who are pregnant or breastfeeding
  • Subjects with an active severe infection, some treated infections and with an expected or with an unexplained fever >38.3°C during screening visits or on their first day of study drug administration.
  • Subjects with some current or prior heart conditions
  • Subjects taking medications that are known to prolong the may not be eligible
  • Subjects with immediately life-threatening, severe complications of leukemia such as uncontrolled bleeding, pneumonia with hypoxia or shock, and/or disseminated intravascular coagulation
  • Some subjects with some current or prior gastrointestinal or liver diseases
  • Subjects with inadequate organ function as defined by the protocol
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    Part 1 Dose Escalation Cohorts

    Patients from each cohort will be administered HMPL-306 orally QD

    Drug: HMPL-306

  • Experimental
    Part 2 Dose Expansion Cohorts

    Patients from each cohort will be administered HMPL-306 orally QD at the recommended phase 2 dose

    Drug: HMPL-306

Interventions

  • Administered orally QD in a 28-day continuous dosing treatment cycle

06

What researchers measure

Primary outcomes

  1. Part 1: Recommended Phase 2 Dose (RP2D) of HMPL-306

    RP2D determination took the following criteria under consideration: determination of maximum tolerated dose (MTD) achieved during the dose escalation part and assessment of safety, pharmacokinetics (PK) and pharmacodynamics (PD). The modified toxicity probability interval-2 design was used to perform dose escalation and planned to determine MTD/RP2D.

    Time frame: From the first dose of study drug (Day 1) up to Day 28 of Cycle 1

  2. Part 1: Number of Patients With Dose-limiting Toxicities (DLTs)

    DLT:occurrence of any of following treatment-emergent adverse events (TEAEs) during DLT assessment window unless clearly unrelated to study drug/judged by investigator as not clinically significant: 1. Non-hematologic:TEAEs Grade \>=4, Grade 3 except those which recovered to Grade \<=1 within 3 days after supportive therapy administered for nausea,vomiting,diarrhea,constipation,fatigue,electrolyte imbalance;Grade 3 hypothyroidism, adrenal gland or pituitary insufficiency, and inflammatory reactions at tumor site \& Grade 3 hypertension downgraded to Grade \<=1 within 1 week with appropriate supportive therapy. 2. Hematologic:Grade \>=3 febrile neutropenia;Grade 4 neutropenia or thrombocytopenia;Grade 3 thrombocytopenia with clinically significant bleeding in addition to that requiring transfusion;Grade 4 anemia requiring a dose delay of \>=14 days. 3. Any life-threatening complication/abnormality not covered in National Cancer Institute Common Terminology Criteria for AEs version(v) 5.0.

    Time frame: From the first dose of study drug (Day 1) up to Day 28 of Cycle 1

  3. Parts 1 and 2: Number of Patients With Treatment-Emergent Adverse Events and Treatment-Emergent Serious Adverse Events (TESAEs)

    AE:unfavorable,unintended sign,symptom or disease temporally associated with use of study drug or other protocol-imposed drug, whether or not considered drug related. SAE:AE that resulted in death, was life threatening, inpatient hospitalization/prolongation of existing hospitalization, persistent/significant incapacity or substantial disruption of ability to conduct normal life functions, congenital anomaly/birth defect, important medical event that jeopardized patient and required medical/surgical intervention to prevent above outcome or signs, symptoms or clinical sequelae of suspected overdose of either study drug or a concomitant medication. TEAE:AE with onset on/after start of study drug until 30 days after last dose or prior to start of subsequent anti-tumor therapy, or AE with onset before start of study drug but worsened in severity after study drug administration or beyond 30 days after last dose or after start of subsequent anti-tumor therapy and treatment-related SAEs.

    Time frame: From the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 43 months for Part 1

Secondary outcomes

  1. Parts 1 and 2: Objective Response Rate (ORR)

    ORR by response evaluation criteria in solid tumors (RECIST) v1.1 was defined as the percentage of patients with confirmed best overall response (BOR) of complete response (CR) or partial response (PR) as determined by the investigator. CR: disappearance of all target lesions. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. ORR by response assessment in neuro-oncology criteria (RANO) was defined as the percentage of patients with a BOR of CR or PR or minor response (MR) as determined by the investigator using RANO criteria mentioned in protocol for glioma patients.

    Time frame: Tumor assessments performed every 8 weeks (+/-1 week) from Cycle 1 Day 1 for the first 24 weeks and every 12 weeks (+/-2 weeks) thereafter until end of treatment or end of efficacy follow-up period, approximately 47 months for Part 1

  2. Parts 1 and 2: Disease Control Rate (DCR)

    DCR by RECIST v1.1 was defined as percentage of patients with BOR of CR, PR, or stable disease (SD) lasting at least 7 weeks as determined by investigator.CR: disappearance of all target lesions.PR: at least a 30% decrease in sum of diameters of target lesions, taking as reference baseline sum of diameters.SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for Pd, taking as reference the smallest sum on study. Pd: at least 20% increase in sum of diameters of target lesions, taking as reference smallest sum on study (nadir), including baseline. In addition to relative increase of 20%, sum must also demonstrate an absolute increase of at least 5 millimeters (mm). The appearance of 1 or more new lesions was also considered progression. DCR by RANO was defined as percentage of patients with BOR of CR, PR, MR, or SD lasting at least 7 weeks as determined by investigator using RANO criteria mentioned in protocol for glioma patients.

    Time frame: Tumor assessments performed every 8 weeks (+/-1 week) from Cycle 1 Day 1 for the first 24 weeks and every 12 weeks (+/-2 weeks) thereafter until end of treatment or end of efficacy follow-up period, approximately 47 months for Part 1

  3. Parts 1 and 2: Duration of Response (DoR)

    DoR by RECIST v1.1 was defined as the time from the first occurrence of confirmed PR or confirmed CR until Pd or death, whichever came first. CR: disappearance of all target lesions. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. Pd: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (nadir), including baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered progression. DoR by RANO was defined as the time from the first occurrence of CR or PR or MR using RANO criteria mentioned in protocol for glioma patients, until disease progression or death, whichever comes first. Due to early study termination, Part 2 was never initiated.

    Time frame: Tumor assessments performed every 8 weeks (+/-1 week) from Cycle 1 Day 1 for the first 24 weeks and every 12 weeks (+/-2 weeks) thereafter until end of treatment or end of efficacy follow-up period, approximately 47 months for Part 1

  4. Parts 1 and 2: Time to Response (TTR)

    TTR by RECIST v1.1 was defined as the time from start of study treatment until the date of first documented objective response, either confirmed CR or confirmed PR (whichever status was recorded first). CR: disappearance of all target lesions. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. TTR by RANO was defined as the time from start of study treatment until the date of first documented objective response, either CR or PR or MR (whichever status was recorded first) using RANO criteria mentioned in protocol for glioma patients. Due to early study termination, Part 2 was never initiated.

    Time frame: Tumor assessments performed every 8 weeks (+/-1 week) from Cycle 1 Day 1 for the first 24 weeks and every 12 weeks (+/-2 weeks) thereafter until end of treatment or end of efficacy follow-up period, approximately 47 months for Part 1

  5. Parts 1 and 2: Progression-free Survival (PFS)

    PFS was defined as the time from the date of first administration of study drug until the first radiographic documentation of objective progression as assessed by investigator using RECIST v1.1 or RANO criteria for glioma patients, or death from any cause. As per RECIST v1.1: Pd: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (nadir), including baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of 1 or more new lesions was also considered progression. Criteria for RANO as mentioned in protocol.

    Time frame: Tumor assessments performed every 8 weeks (+/-1 week) from Cycle 1 Day 1 for the first 24 weeks and every 12 weeks (+/-2 weeks) thereafter until end of treatment or end of efficacy follow-up period, approximately 47 months for Part 1

  6. Parts 1 and 2: Maximum Observed Plasma Concentration (Cmax) of HMPL-306

    Blood samples were collected at the specified timepoints to determine Cmax of HMPL-306.

    Time frame: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8 and 24 hours post-dose on Day 1 of Cycles 1 and 2 for Part 1

  7. Parts 1 and 2: Time to Peak Plasma Concentration (Tmax) of HMPL-306

    Blood samples were collected at the specified timepoints to determine Tmax of HMPL-306.

    Time frame: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8 and 24 hours post-dose on Day 1 of Cycles 1 and 2 for Part 1

  8. Parts 1 and 2: Area Under the Plasma Concentration-Time Curve From 0 to 24 Hours (AUC0-24) of HMPL-306

    Blood samples were collected at the specified timepoints to determine AUC0-24 of HMPL-306.

    Time frame: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8 and 24 hours post-dose on Day 1 of Cycles 1 and 2 for Part 1

  9. Parts 1 and 2: Maximum Inhibition Rate of Plasma 2-Hydroxyglutaric Acid (2-HG)

    Blood samples were collected at the specified timepoints to determine plasma concentrations of 2-HG which was a PD marker. The maximum inhibition rate of 2-HG for patients in different dose groups is presented.

    Time frame: From screening (Day -28) until end of treatment, approximately 42 months for Part 1

07

Results

Posted Mar 27, 2026
Limitations and caveats
The study was terminated based on strategic evaluation of the clinical development of HMPL-306 with no safety concerns.

Participant flow

This Phase 1, open-label study was conducted in patients with locally advanced or metastatic solid tumors with isocitrate dehydrogenase (IDH) mutations and consisted of dose escalation part (Part 1) and dose expansion part (Part 2).

Participant flow — Overall Study
MilestonePart 1: Cohort-1: HMPL-306 50 mgPart 1: Cohort-2: HMPL-306 100 mgPart 1: Cohort-3: HMPL-306 150 mgPart 1: Cohort-4: HMPL-306 200 mgPart 1: Cohort-5: HMPL-306 250 mgPart 1: Cohort-6: HMPL-306 300 mgPart 1: Cohort-7: HMPL-306 350 mgPart 1: Cohort-8: HMPL-306 400 mg
Started335126445
Completed00000000
Not completed335126445
Withdrew: Other333113435
Withdrew: Withdrawal by subject00101010
Withdrew: Death00112000

Outcome measures

PrimaryPart 1: Recommended Phase 2 Dose (RP2D) of HMPL-306

RP2D determination took the following criteria under consideration: determination of maximum tolerated dose (MTD) achieved during the dose escalation part and assessment of safety, pharmacokinetics (PK) and pharmacodynamics (PD). The modified toxicity probability interval-2 design was used to perform dose escalation and planned to determine MTD/RP2D.

Time frame:
From the first dose of study drug (Day 1) up to Day 28 of Cycle 1
Reported as:
Number · milligrams
Part 1: Recommended Phase 2 Dose (RP2D) of HMPL-306
milligramsPart 1: Cohorts-1 to 8: HMPL-306
Part 1: Recommended Phase 2 Dose (RP2D) of HMPL-306NA
PrimaryPart 1: Number of Patients With Dose-limiting Toxicities (DLTs)

DLT:occurrence of any of following treatment-emergent adverse events (TEAEs) during DLT assessment window unless clearly unrelated to study drug/judged by investigator as not clinically significant: 1. Non-hematologic:TEAEs Grade \>=4, Grade 3 except those which recovered to Grade \<=1 within 3 days after supportive therapy administered for nausea,vomiting,diarrhea,constipation,fatigue,electrolyte imbalance;Grade 3 hypothyroidism, adrenal gland or pituitary insufficiency, and inflammatory reactions at tumor site \& Grade 3 hypertension downgraded to Grade \<=1 within 1 week with appropriate supportive therapy. 2. Hematologic:Grade \>=3 febrile neutropenia;Grade 4 neutropenia or thrombocytopenia;Grade 3 thrombocytopenia with clinically significant bleeding in addition to that requiring transfusion;Grade 4 anemia requiring a dose delay of \>=14 days. 3. Any life-threatening complication/abnormality not covered in National Cancer Institute Common Terminology Criteria for AEs version(v) 5.0.

Time frame:
From the first dose of study drug (Day 1) up to Day 28 of Cycle 1
Reported as:
Count of participants · Participants
Part 1: Number of Patients With Dose-limiting Toxicities (DLTs)
ParticipantsPart 1: Cohort-1: HMPL-306 50 mgPart 1: Cohort-2: HMPL-306 100 mgPart 1: Cohort-3: HMPL-306 150 mgPart 1: Cohort-4: HMPL-306 200 mgPart 1: Cohort-5: HMPL-306 250 mgPart 1: Cohort-6: HMPL-306 300 mgPart 1: Cohort-7: HMPL-306 350 mgPart 1: Cohort-8: HMPL-306 400 mg
Part 1: Number of Patients With Dose-limiting Toxicities (DLTs)00001000
PrimaryParts 1 and 2: Number of Patients With Treatment-Emergent Adverse Events and Treatment-Emergent Serious Adverse Events (TESAEs)

AE:unfavorable,unintended sign,symptom or disease temporally associated with use of study drug or other protocol-imposed drug, whether or not considered drug related. SAE:AE that resulted in death, was life threatening, inpatient hospitalization/prolongation of existing hospitalization, persistent/significant incapacity or substantial disruption of ability to conduct normal life functions, congenital anomaly/birth defect, important medical event that jeopardized patient and required medical/surgical intervention to prevent above outcome or signs, symptoms or clinical sequelae of suspected overdose of either study drug or a concomitant medication. TEAE:AE with onset on/after start of study drug until 30 days after last dose or prior to start of subsequent anti-tumor therapy, or AE with onset before start of study drug but worsened in severity after study drug administration or beyond 30 days after last dose or after start of subsequent anti-tumor therapy and treatment-related SAEs.

Time frame:
From the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 43 months for Part 1
Reported as:
Count of participants · Participants
Parts 1 and 2: Number of Patients With Treatment-Emergent Adverse Events and Treatment-Emergent Serious Adverse Events (TESAEs)
ParticipantsPart 1: Cohort-1: HMPL-306 50 mgPart 1: Cohort-2: HMPL-306 100 mgPart 1: Cohort-3: HMPL-306 150 mgPart 1: Cohort-4: HMPL-306 200 mgPart 1: Cohort-5: HMPL-306 250 mgPart 1: Cohort-6: HMPL-306 300 mgPart 1: Cohort-7: HMPL-306 350 mgPart 1: Cohort-8: HMPL-306 400 mg
TEAEs335115445
TESAEs11210211
SecondaryParts 1 and 2: Objective Response Rate (ORR)

ORR by response evaluation criteria in solid tumors (RECIST) v1.1 was defined as the percentage of patients with confirmed best overall response (BOR) of complete response (CR) or partial response (PR) as determined by the investigator. CR: disappearance of all target lesions. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. ORR by response assessment in neuro-oncology criteria (RANO) was defined as the percentage of patients with a BOR of CR or PR or minor response (MR) as determined by the investigator using RANO criteria mentioned in protocol for glioma patients.

Time frame:
Tumor assessments performed every 8 weeks (+/-1 week) from Cycle 1 Day 1 for the first 24 weeks and every 12 weeks (+/-2 weeks) thereafter until end of treatment or end of efficacy follow-up period, approximately 47 months for Part 1
Reported as:
Number · percentage of patients
Parts 1 and 2: Objective Response Rate (ORR)
percentage of patientsPart 1: Cohort-1: HMPL-306 50 mgPart 1: Cohort-2: HMPL-306 100 mgPart 1: Cohort-3: HMPL-306 150 mgPart 1: Cohort-4: HMPL-306 200 mgPart 1: Cohort-5: HMPL-306 250 mgPart 1: Cohort-6: HMPL-306 300 mgPart 1: Cohort-7: HMPL-306 350 mgPart 1: Cohort-8: HMPL-306 400 mg
Parts 1 and 2: Objective Response Rate (ORR)0 (0.0 to 70.8)33.3 (0.8 to 90.6)0 (0.0 to 60.2)8.3 (0.2 to 38.5)20.0 (0.5 to 71.6)0 (0.0 to 60.2)0 (0.0 to 84.2)0 (0 to 52.2)
SecondaryParts 1 and 2: Disease Control Rate (DCR)

DCR by RECIST v1.1 was defined as percentage of patients with BOR of CR, PR, or stable disease (SD) lasting at least 7 weeks as determined by investigator.CR: disappearance of all target lesions.PR: at least a 30% decrease in sum of diameters of target lesions, taking as reference baseline sum of diameters.SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for Pd, taking as reference the smallest sum on study. Pd: at least 20% increase in sum of diameters of target lesions, taking as reference smallest sum on study (nadir), including baseline. In addition to relative increase of 20%, sum must also demonstrate an absolute increase of at least 5 millimeters (mm). The appearance of 1 or more new lesions was also considered progression. DCR by RANO was defined as percentage of patients with BOR of CR, PR, MR, or SD lasting at least 7 weeks as determined by investigator using RANO criteria mentioned in protocol for glioma patients.

Time frame:
Tumor assessments performed every 8 weeks (+/-1 week) from Cycle 1 Day 1 for the first 24 weeks and every 12 weeks (+/-2 weeks) thereafter until end of treatment or end of efficacy follow-up period, approximately 47 months for Part 1
Reported as:
Number · percentage of patients
Parts 1 and 2: Disease Control Rate (DCR)
percentage of patientsPart 1: Cohort-1: HMPL-306 50 mgPart 1: Cohort-2: HMPL-306 100 mgPart 1: Cohort-3: HMPL-306 150 mgPart 1: Cohort-4: HMPL-306 200 mgPart 1: Cohort-5: HMPL-306 250 mgPart 1: Cohort-6: HMPL-306 300 mgPart 1: Cohort-7: HMPL-306 350 mgPart 1: Cohort-8: HMPL-306 400 mg
Parts 1 and 2: Disease Control Rate (DCR)0 (0.0 to 70.8)66.7 (9.4 to 99.2)50.0 (6.8 to 93.2)66.7 (34.9 to 90.1)60.0 (14.7 to 94.7)75.0 (19.4 to 99.4)50.0 (1.3 to 98.7)40.0 (5.3 to 85.3)
SecondaryParts 1 and 2: Duration of Response (DoR)

DoR by RECIST v1.1 was defined as the time from the first occurrence of confirmed PR or confirmed CR until Pd or death, whichever came first. CR: disappearance of all target lesions. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. Pd: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (nadir), including baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered progression. DoR by RANO was defined as the time from the first occurrence of CR or PR or MR using RANO criteria mentioned in protocol for glioma patients, until disease progression or death, whichever comes first. Due to early study termination, Part 2 was never initiated.

Time frame:
Tumor assessments performed every 8 weeks (+/-1 week) from Cycle 1 Day 1 for the first 24 weeks and every 12 weeks (+/-2 weeks) thereafter until end of treatment or end of efficacy follow-up period, approximately 47 months for Part 1
Reported as:
Median · months
Parts 1 and 2: Duration of Response (DoR)
monthsPart 1: Cohort-1: HMPL-306 50 mgPart 1: Cohort-2: HMPL-306 100 mgPart 1: Cohort-3: HMPL-306 150 mgPart 1: Cohort-4: HMPL-306 200 mgPart 1: Cohort-5: HMPL-306 250 mgPart 1: Cohort-6: HMPL-306 300 mgPart 1: Cohort-7: HMPL-306 350 mgPart 1: Cohort-8: HMPL-306 400 mg
Parts 1 and 2: Duration of Response (DoR)—NA (NA to NA)—16.8 (NA to NA)NA (NA to NA)———
SecondaryParts 1 and 2: Time to Response (TTR)

TTR by RECIST v1.1 was defined as the time from start of study treatment until the date of first documented objective response, either confirmed CR or confirmed PR (whichever status was recorded first). CR: disappearance of all target lesions. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. TTR by RANO was defined as the time from start of study treatment until the date of first documented objective response, either CR or PR or MR (whichever status was recorded first) using RANO criteria mentioned in protocol for glioma patients. Due to early study termination, Part 2 was never initiated.

Time frame:
Tumor assessments performed every 8 weeks (+/-1 week) from Cycle 1 Day 1 for the first 24 weeks and every 12 weeks (+/-2 weeks) thereafter until end of treatment or end of efficacy follow-up period, approximately 47 months for Part 1
Reported as:
Median · months
Parts 1 and 2: Time to Response (TTR)
monthsPart 1: Cohort-1: HMPL-306 50 mgPart 1: Cohort-2: HMPL-306 100 mgPart 1: Cohort-3: HMPL-306 150 mgPart 1: Cohort-4: HMPL-306 200 mgPart 1: Cohort-5: HMPL-306 250 mgPart 1: Cohort-6: HMPL-306 300 mgPart 1: Cohort-7: HMPL-306 350 mgPart 1: Cohort-8: HMPL-306 400 mg
Parts 1 and 2: Time to Response (TTR)—2.1 (NA to NA)—3.7 (NA to NA)22.1 (NA to NA)———
SecondaryParts 1 and 2: Progression-free Survival (PFS)

PFS was defined as the time from the date of first administration of study drug until the first radiographic documentation of objective progression as assessed by investigator using RECIST v1.1 or RANO criteria for glioma patients, or death from any cause. As per RECIST v1.1: Pd: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (nadir), including baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of 1 or more new lesions was also considered progression. Criteria for RANO as mentioned in protocol.

Time frame:
Tumor assessments performed every 8 weeks (+/-1 week) from Cycle 1 Day 1 for the first 24 weeks and every 12 weeks (+/-2 weeks) thereafter until end of treatment or end of efficacy follow-up period, approximately 47 months for Part 1
Reported as:
Median · months
Parts 1 and 2: Progression-free Survival (PFS)
monthsPart 1: Cohort-1: HMPL-306 50 mgPart 1: Cohort-2: HMPL-306 100 mgPart 1: Cohort-3: HMPL-306 150 mgPart 1: Cohort-4: HMPL-306 200 mgPart 1: Cohort-5: HMPL-306 250 mgPart 1: Cohort-6: HMPL-306 300 mgPart 1: Cohort-7: HMPL-306 350 mgPart 1: Cohort-8: HMPL-306 400 mg
Parts 1 and 2: Progression-free Survival (PFS)1.9 (1.8 to NA)5.5 (1.8 to NA)2.7 (0.8 to NA)5.6 (1.7 to 12.9)3.7 (1.7 to NA)8.3 (1.6 to NA)NA (NA to NA)1.9 (0.6 to NA)
SecondaryParts 1 and 2: Maximum Observed Plasma Concentration (Cmax) of HMPL-306

Blood samples were collected at the specified timepoints to determine Cmax of HMPL-306.

Time frame:
Pre-dose and 0.5, 1, 2, 3, 4, 6, 8 and 24 hours post-dose on Day 1 of Cycles 1 and 2 for Part 1
Reported as:
Geometric mean · nanogram/milliliter (ng/mL)
Parts 1 and 2: Maximum Observed Plasma Concentration (Cmax) of HMPL-306
nanogram/milliliter (ng/mL)Part 1: Cohort-1: HMPL-306 50 mgPart 1: Cohort-2: HMPL-306 100 mgPart 1: Cohort-3: HMPL-306 150 mgPart 1: Cohort-4: HMPL-306 200 mgPart 1: Cohort-5: HMPL-306 250 mgPart 1: Cohort-6: HMPL-306 300 mgPart 1: Cohort-7: HMPL-306 350 mgPart 1: Cohort-8: HMPL-306 400 mg
Cycle 1 Day 1181 ± 17.5487 ± 35.1365 ± 26.6550 ± 43.2596 ± 35.6645 ± 38.9670 ± 51.9885 ± 45.7
Cycle 2 Day 1414 ± 34.3891 ± 30.11025 ± 6.01633 ± 26.01721 ± 15.51943 ± 71.71758 ± 61.23665 ± 36.1
SecondaryParts 1 and 2: Time to Peak Plasma Concentration (Tmax) of HMPL-306

Blood samples were collected at the specified timepoints to determine Tmax of HMPL-306.

Time frame:
Pre-dose and 0.5, 1, 2, 3, 4, 6, 8 and 24 hours post-dose on Day 1 of Cycles 1 and 2 for Part 1
Reported as:
Median · hour
Parts 1 and 2: Time to Peak Plasma Concentration (Tmax) of HMPL-306
hourPart 1: Cohort-1: HMPL-306 50 mgPart 1: Cohort-2: HMPL-306 100 mgPart 1: Cohort-3: HMPL-306 150 mgPart 1: Cohort-4: HMPL-306 200 mgPart 1: Cohort-5: HMPL-306 250 mgPart 1: Cohort-6: HMPL-306 300 mgPart 1: Cohort-7: HMPL-306 350 mgPart 1: Cohort-8: HMPL-306 400 mg
Cycle 1 Day 12.17 (2.02 to 2.17)1.97 (1.00 to 3.08)2.12 (1.15 to 3.02)2.55 (1.00 to 4.22)2.20 (1.07 to 3.02)2.92 (2.03 to 6.00)2.92 (2.15 to 3.00)2.90 (2.00 to 3.02)
Cycle 2 Day 12.12 (2.10 to 2.13)1.10 (1.00 to 4.17)2.05 (1.08 to 4.08)1.17 (0.533 to 3.15)2.97 (0.983 to 3.75)2.00 (1.03 to 3.00)2.00 (1.00 to 3.00)1.96 (1.03 to 3.05)
SecondaryParts 1 and 2: Area Under the Plasma Concentration-Time Curve From 0 to 24 Hours (AUC0-24) of HMPL-306

Blood samples were collected at the specified timepoints to determine AUC0-24 of HMPL-306.

Time frame:
Pre-dose and 0.5, 1, 2, 3, 4, 6, 8 and 24 hours post-dose on Day 1 of Cycles 1 and 2 for Part 1
Reported as:
Geometric mean · hour*ng/mL
Parts 1 and 2: Area Under the Plasma Concentration-Time Curve From 0 to 24 Hours (AUC0-24) of HMPL-306
hour*ng/mLPart 1: Cohort-1: HMPL-306 50 mgPart 1: Cohort-2: HMPL-306 100 mgPart 1: Cohort-3: HMPL-306 150 mgPart 1: Cohort-4: HMPL-306 200 mgPart 1: Cohort-5: HMPL-306 250 mgPart 1: Cohort-6: HMPL-306 300 mgPart 1: Cohort-7: HMPL-306 350 mgPart 1: Cohort-8: HMPL-306 400 mg
Cycle 1 Day 11625 ± 19.52894 ± 31.43084 ± 21.35007 ± 36.05045 ± 33.98315 ± 52.87556 ± 24.59712 ± 37.5
Cycle 2 Day 17033 ± 65.912907 ± 30.716710 ± 12.327427 ± 26.226616 ± 24.538461 ± 64.628342 ± 36.958900 ± 48.5
SecondaryParts 1 and 2: Maximum Inhibition Rate of Plasma 2-Hydroxyglutaric Acid (2-HG)

Blood samples were collected at the specified timepoints to determine plasma concentrations of 2-HG which was a PD marker. The maximum inhibition rate of 2-HG for patients in different dose groups is presented.

Time frame:
From screening (Day -28) until end of treatment, approximately 42 months for Part 1
Reported as:
Mean · percentage of inhibition
Parts 1 and 2: Maximum Inhibition Rate of Plasma 2-Hydroxyglutaric Acid (2-HG)
percentage of inhibitionPart 1: Cohort-1: HMPL-306 50 mgPart 1: Cohort-2: HMPL-306 100 mgPart 1: Cohort-3: HMPL-306 150 mgPart 1: Cohort-4: HMPL-306 200 mgPart 1: Cohort-5: HMPL-306 250 mgPart 1: Cohort-6: HMPL-306 300 mgPart 1: Cohort-7: HMPL-306 350 mgPart 1: Cohort-8: HMPL-306 400 mg
Parts 1 and 2: Maximum Inhibition Rate of Plasma 2-Hydroxyglutaric Acid (2-HG)39.04 ± 17.7369.15 ± 3.5276.93 ± 17.1780.79 ± 12.5453.83 ± 6.6895.74 ± 4.4583.22 ± 11.0387.33 ± 6.29

Adverse events

Collected over Adverse events were collected from the from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 43 months for Part 1. All-cause mortality (deaths) was collected from the first dose of study drug (Day 1) up to end of follow-up, approximately 47 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: Cohort-1: HMPL-306 50 mg0/3 (0%)1/3 (33.3%)3/3 (100%)
Part 1: Cohort-2: HMPL-306 100 mg0/3 (0%)1/3 (33.3%)3/3 (100%)
Part 1: Cohort-3: HMPL-306 150 mg1/5 (20%)2/5 (40%)4/5 (80%)
Part 1: Cohort-4: HMPL-306 200 mg1/12 (8.3%)1/12 (8.3%)11/12 (91.7%)
Part 1: Cohort-5: HMPL-306 250 mg2/6 (33.3%)0/6 (0%)5/6 (83.3%)
Part 1: Cohort-6: HMPL-306 300 mg0/4 (0%)2/4 (50%)4/4 (100%)
Part 1: Cohort-7: HMPL-306 350 mg0/4 (0%)1/4 (25%)4/4 (100%)
Part 1: Cohort-8: HMPL-306 400 mg0/5 (0%)1/5 (20%)5/5 (100%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventPart 1: Cohort-1: HMPL-306 50 mgPart 1: Cohort-2: HMPL-306 100 mgPart 1: Cohort-3: HMPL-306 150 mgPart 1: Cohort-4: HMPL-306 200 mgPart 1: Cohort-5: HMPL-306 250 mgPart 1: Cohort-6: HMPL-306 300 mgPart 1: Cohort-7: HMPL-306 350 mgPart 1: Cohort-8: HMPL-306 400 mg
BacteraemiaInfections and infestations1/30/30/50/12—0/40/40/5
Device related infectionInfections and infestations1/30/30/50/12—0/40/40/5
Wound infectionInfections and infestations0/31/30/50/12—0/40/40/5
Urinary tract infectionInfections and infestations0/30/30/50/12—1/40/40/5
EpilepsyNervous system disorders0/30/31/50/12—1/40/40/5
PyrexiaGeneral disorders0/30/30/50/12—0/41/40/5
Depressed level of consciousnessNervous system disorders0/30/30/50/12—0/40/41/5
Neoplasm swellingNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/30/30/50/12—0/40/41/5
Tumour haemorrhageNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/30/31/50/12—0/40/40/5
Biliary obstructionHepatobiliary disorders0/30/31/50/12—0/40/40/5
Most frequent other events
Showing 10 of 109
Most frequent other events
EventPart 1: Cohort-1: HMPL-306 50 mgPart 1: Cohort-2: HMPL-306 100 mgPart 1: Cohort-3: HMPL-306 150 mgPart 1: Cohort-4: HMPL-306 200 mgPart 1: Cohort-5: HMPL-306 250 mgPart 1: Cohort-6: HMPL-306 300 mgPart 1: Cohort-7: HMPL-306 350 mgPart 1: Cohort-8: HMPL-306 400 mg
NauseaGastrointestinal disorders0/31/31/51/121/62/42/40/5
VomitingGastrointestinal disorders0/31/30/50/121/62/41/40/5
Gamma-glutamyltransferase increasedInvestigations0/30/30/50/120/60/42/40/5
Muscle spasmsMusculoskeletal and connective tissue disorders0/30/30/50/120/62/40/40/5
ThrombocytopeniaBlood and lymphatic system disorders0/30/30/50/120/62/40/40/5
Decreased appetiteMetabolism and nutrition disorders0/30/31/50/121/61/41/42/5
HeadacheNervous system disorders0/30/30/52/120/61/40/42/5
AstheniaGeneral disorders0/30/30/53/120/61/41/42/5
InsomniaPsychiatric disorders0/30/30/50/121/60/40/42/5
DiarrhoeaGastrointestinal disorders0/30/30/52/122/61/41/41/5

Baseline characteristics

The safety analysis set included all enrolled patients who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Part 1: Cohort-1: HMPL-306 50 mgPart 1: Cohort-2: HMPL-306 100 mgPart 1: Cohort-3: HMPL-306 150 mgPart 1: Cohort-4: HMPL-306 200 mgPart 1: Cohort-5: HMPL-306 250 mgPart 1: Cohort-6: HMPL-306 300 mgPart 1: Cohort-7: HMPL-306 350 mgPart 1: Cohort-8: HMPL-306 400 mgTotal
Mean48.3 ± 19.0454.0 ± 9.6455.4 ± 10.6953.0 ± 19.2952.3 ± 9.7154.8 ± 11.5357.3 ± 5.5653.0 ± 16.3253.5 ± 13.67
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: Cohort-1: HMPL-306 50 mgPart 1: Cohort-2: HMPL-306 100 mgPart 1: Cohort-3: HMPL-306 150 mgPart 1: Cohort-4: HMPL-306 200 mgPart 1: Cohort-5: HMPL-306 250 mgPart 1: Cohort-6: HMPL-306 300 mgPart 1: Cohort-7: HMPL-306 350 mgPart 1: Cohort-8: HMPL-306 400 mgTotal
Female2205320317
Male1157324225
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1: Cohort-1: HMPL-306 50 mgPart 1: Cohort-2: HMPL-306 100 mgPart 1: Cohort-3: HMPL-306 150 mgPart 1: Cohort-4: HMPL-306 200 mgPart 1: Cohort-5: HMPL-306 250 mgPart 1: Cohort-6: HMPL-306 300 mgPart 1: Cohort-7: HMPL-306 350 mgPart 1: Cohort-8: HMPL-306 400 mgTotal
Hispanic or Latino000310004
Not Hispanic or Latino2359544537
Unknown or Not Reported100000001
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part 1: Cohort-1: HMPL-306 50 mgPart 1: Cohort-2: HMPL-306 100 mgPart 1: Cohort-3: HMPL-306 150 mgPart 1: Cohort-4: HMPL-306 200 mgPart 1: Cohort-5: HMPL-306 250 mgPart 1: Cohort-6: HMPL-306 300 mgPart 1: Cohort-7: HMPL-306 350 mgPart 1: Cohort-8: HMPL-306 400 mgTotal
Asian010000001
Black or African American001000001
White22411644538
Not Reported100000001
Other000100001
08

Study locations

11 sites
  • Sarcoma Oncology Research Center
    Santa Monica, California 90403, United States
  • Emory University
    Atlanta, Georgia 30322, United States
  • University of Iowa
    Iowa City, Iowa 52242, United States
  • University of Kentucky
    Lexington, Kentucky 40536, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
  • UPMC Hillman Cancer
    Pittsburgh, Pennsylvania 15232, United States
  • Houston Methodist
    Houston, Texas 77030, United States
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Hospital de la Santa creu i Sant Pau
    Barcelona, 08025, Spain
  • Hospital Universitari Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2021 to primary completion in Feb 2025, 47 months.

Results were first posted in Mar 2026, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2021
First posted
Feb 21, 2021
StartActual
Feb 28, 2021
Primary completionActual
Feb 27, 2025
CompletionActual
Feb 27, 2025
Results first posted
Mar 27, 2026
Last update
Mar 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04762602
Lead sponsor
Hutchmed
Responsible party
Sponsor
First posted
Feb 21, 2021
Start date
Feb 28, 2021
Primary completion
Feb 27, 2025
Completion
Feb 27, 2025
Results posted
Mar 27, 2026
Last update
Mar 27, 2026

Study contacts

Bo Zhang
study director · Hutchison Medipharma Limited

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranosidenib

Start the discussion